TDI01 suspension

DRUG2 trials

Sponsors

Beijing Tide Pharmaceutical Co., Ltd

Conditions

GVHD, ChronicIdiopathic Pulmonary Fibrosis

Phase 1

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

Active, not recruitingNCT06169722

Beijing Tide Pharmaceutical Co., LtdGVHD, Chronic

Start: 2024-02-06End: 2027-08-31Target: 60Updated: 2025-09-26

Phase 2

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

Not yet recruitingNCT06102083

Beijing Tide Pharmaceutical Co., LtdIdiopathic Pulmonary Fibrosis

Start: 2023-11-02End: 2026-03-01Target: 120Updated: 2023-11-02

Related Papers

Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.

2026-08-06

TDI01 in the treatment of moderate to severe chronic graft-versus-host disease: Updated results from a multicenter, OPEN-label phase IB/II study (An Update)

Blood2025-11-03